Analysts Set GH Research PLC (NASDAQ:GHRS) Price Target at $40.13

Shares of GH Research PLC (NASDAQ:GHRS) have received an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $40.1250.

A number of research firms recently commented on GHRS. Citizens Jmp increased their price target on GH Research from $39.00 to $42.00 and gave the stock a “market outperform” rating in a research report on Friday, March 6th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research report on Thursday, January 22nd. Citigroup restated a “market outperform” rating on shares of GH Research in a research report on Tuesday, January 6th. Guggenheim set a $34.00 price target on GH Research and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Finally, Needham & Company LLC increased their price target on GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, March 6th.

Institutional Trading of GH Research

Hedge funds have recently modified their holdings of the stock. HighVista Strategies LLC grew its stake in shares of GH Research by 363.0% during the third quarter. HighVista Strategies LLC now owns 241,894 shares of the company’s stock valued at $3,459,000 after purchasing an additional 189,647 shares during the last quarter. CenterBook Partners LP bought a new stake in shares of GH Research during the third quarter valued at approximately $2,376,000. AdvisorShares Investments LLC grew its stake in shares of GH Research by 41.1% during the third quarter. AdvisorShares Investments LLC now owns 53,991 shares of the company’s stock valued at $772,000 after purchasing an additional 15,735 shares during the last quarter. HRT Financial LP bought a new stake in shares of GH Research during the fourth quarter valued at approximately $202,000. Finally, JPMorgan Chase & Co. grew its stake in shares of GH Research by 113.8% during the third quarter. JPMorgan Chase & Co. now owns 13,900 shares of the company’s stock valued at $199,000 after purchasing an additional 7,400 shares during the last quarter. 56.90% of the stock is owned by institutional investors.

GH Research Price Performance

Shares of GHRS opened at $17.00 on Friday. The company has a market capitalization of $1.05 billion, a P/E ratio of -21.25 and a beta of 1.00. GH Research has a one year low of $8.51 and a one year high of $19.51. The business’s 50 day simple moving average is $15.08 and its 200-day simple moving average is $14.54.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Friday, March 6th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. On average, sell-side analysts anticipate that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.